newsfilter
← Latest News
GlobeNewswire·

Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in late Q4 2026 Reports